Antitumor effects of Royal Jelly (RJ).

Publisher Website
Google Scholar
Abstract
Antitumor effect of Royal Jelly (RJ) were investigated employing the transplantable tumors of mouse advance leukemia L1210 and P388 strains and Ehrlich, Sarcoma-180 ascites and solid tumor strains. RJ was administered orally in a prophylactic-therapeutic (30 days before and 30 days after the transplantations of tumor cells) or a therapeutic (30 days after the transplantations of tumor cells) manner. Tumor cells were transplanted i.p. (ascites tumor) or s.c. (solid tumor). The daily dose of RJ was 0 (control), 10, 100, or 1000 mg/kg. In the case of the therapeutic experiments employing advance leukemia L1210 and P388 strains, which gave quite a short survival period of 8 .apprx. 9 days, RJ did not show any antitumor effect. In the case of the therapeutic RJ application employing the Sarcoma-180 ascites tumor, which gave a moderate survival period of 16 days, the increased life span was 9.3 .apprx. 19.3%; and with the Ehrlich ascites tumor (survival period of 22.1 days), the increased life span was 20.4% (RJ 10 mg/kg .cntdot. day) and 17.6% (RJ 1,000 mg/kg .cntdot. day), but no antitumor effect was observed at the dose of 100 mg/kg .cntdot. day. In the case of the therapeutic experiment employing Ehrlich solid tumor, tumor growth inhibition was 25.3 .apprx. 54.8%, where as the use of the prophylactic-therapeutic regimen gave a tumor growth inhibition of 38.3 .apprx. 45.7%. In the case of the therapeutic RJ application employing Sarcoma-180 solid tumor, tumor growth inhibition was 45.1 .apprx. 59.7%, where as the prophylactic-therapeutic regimen gave a tumor growth inhibition of 49.1 .apprx. 56.1%. There results indicate that RJ is not effective against rapidly growing tumors; however, it is effective against slowly growing tumors such as solid tumor.